![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: VWCE |
Gene summary for VWCE |
![]() |
Gene information | Species | Human | Gene symbol | VWCE | Gene ID | 220001 |
Gene name | von Willebrand factor C and EGF domains | |
Gene Alias | URG11 | |
Cytomap | 11q12.2 | |
Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | Q96DN2 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
220001 | VWCE | HCC1_Meng | Human | Liver | HCC | 2.76e-31 | 1.08e-01 | 0.0246 |
220001 | VWCE | HCC2 | Human | Liver | HCC | 3.05e-06 | 2.41e+00 | 0.5341 |
220001 | VWCE | S014 | Human | Liver | HCC | 1.42e-15 | 6.72e-01 | 0.2254 |
220001 | VWCE | S015 | Human | Liver | HCC | 4.65e-14 | 7.79e-01 | 0.2375 |
220001 | VWCE | S016 | Human | Liver | HCC | 1.60e-21 | 7.08e-01 | 0.2243 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Cervix | N_HPV | ![]() |
Endometrium | AEH | ![]() |
Endometrium | EEC | ![]() |
Prostate | BPH | ![]() |
Prostate | Tumor | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000961511 | Liver | HCC | response to virus | 210/7958 | 367/18723 | 7.32e-09 | 1.86e-07 | 210 |
GO:00985861 | Liver | HCC | cellular response to virus | 57/7958 | 84/18723 | 2.30e-06 | 3.11e-05 | 57 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
VWCE | SNV | Missense_Mutation | c.1391N>A | p.Thr464Asn | p.T464N | Q96DN2 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
VWCE | SNV | Missense_Mutation | c.2755N>T | p.Arg919Cys | p.R919C | Q96DN2 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.446) | TCGA-AC-A23C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | chemo | CR | |
VWCE | SNV | Missense_Mutation | c.2345C>G | p.Ser782Cys | p.S782C | Q96DN2 | protein_coding | deleterious_low_confidence(0.01) | benign(0.001) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
VWCE | SNV | Missense_Mutation | c.872N>A | p.Ala291Asp | p.A291D | Q96DN2 | protein_coding | deleterious(0) | possibly_damaging(0.583) | TCGA-AO-A0J4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
VWCE | SNV | Missense_Mutation | c.2693N>T | p.Ala898Val | p.A898V | Q96DN2 | protein_coding | tolerated_low_confidence(0.05) | benign(0.003) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
VWCE | SNV | Missense_Mutation | c.2569C>G | p.Leu857Val | p.L857V | Q96DN2 | protein_coding | tolerated_low_confidence(0.07) | benign(0.341) | TCGA-BH-A18P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
VWCE | SNV | Missense_Mutation | c.2575N>G | p.Leu859Val | p.L859V | Q96DN2 | protein_coding | tolerated_low_confidence(0.21) | benign(0.034) | TCGA-D8-A1XL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide+tamoxifen | SD | |
VWCE | SNV | Missense_Mutation | rs763337070 | c.1513N>A | p.Gly505Ser | p.G505S | Q96DN2 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
VWCE | SNV | Missense_Mutation | novel | c.815N>G | p.Ser272Cys | p.S272C | Q96DN2 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-C5-A905-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
VWCE | SNV | Missense_Mutation | novel | c.769N>C | p.Asp257His | p.D257H | Q96DN2 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |